Penn studies show hope for multiple cancers with pembrolizumab combination therapies

(University of Pennsylvania School of Medicine) The combination of pembrolizumab and the checkpoint inhibitor known as epacadostat is leading to promising responses and is generally well tolerated in patients with triple-negative breast cancer, non-small cell lung cancer, squamous cell cancer of the head and neck, and several other cancers, according to researchers from the Abramson Cancer Center of the University of Pennsylvania. Their findings also showed that adding pembrolizumab to standard therapies for breast cancer improved the number of patients achieving a pathological complete response.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news